TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare

TVM Capital Healthcare Announces EUR 16 Million Investment into neurocare

neurocare is revolutionizing mental health care by providing innovative methods and tools based on neurostimulation and other technologies to help clinicians deliver personalized treatments with sustainable clinical outcomes for patients.  The investment will enable the company to execute on its growth plans, including expansion into the MENA region.

Dubai, Munich - 24. April 2024 - TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and Singapore, today announced a EUR 16 million investment into Munich-headquartered neurocare group AG (neurocare), a leading innovator in personalized mental health care, providing solutions to empower clinicians to deliver best care to their patients. TVM Capital Healthcare's investment will enable neurocare to execute on its international growth plans, including expansion in the US and market entry into the Kingdom of Saudi Arabia, as well as support the development of new hardware and software innovations. It is the ninth investment of TVM Capital Healthcare to improve local access to quality healthcare in the MENA region.

neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing individualized therapy plans that are designed to lead to strong, sustainable clinical outcomes. neurocare’s offering is used in the Company’s own clinics in the US, Europe and Australia, as well as in a growing number of third-party clinics globally.

Globally, 12.9% of people are affected by mental disorders (WHO), causing tremendous direct and indirect costs, expected to increase from $2.5 trillion in 2010 to $6 trillion by 2030. The number of patients diagnosed with mental illnesses doubled during the COVID pandemic. The treatment of mental health conditions remains nevertheless significantly lacking in most countries, leaving a considerable portion of the population without the necessary support, and presenting a unique growth opportunity for companies like neurocare offering innovative non-invasive treatments with superior clinical outcomes.

Tristan de Boysson, Managing Partner, TVM Capital Healthcare, stated: "This investment is part of our strategy of investing in highly innovative, best-in-class healthcare solutions that improve access to quality care across the globe. A special objective of the Firm is improving the healthcare infrastructure in Saudi Arabia and the wider MENA Region. Most mental health clinics in this region rely on traditional behavioural and drug care therapy methods, thus creating a first mover advantage for companies like neurocare, offering innovative mental health treatments with superior clinical outcomes. We are excited about bringing this offering to the people in the MENA Region and are looking forward to working together with the neurocare management team to realize this objective.”

Thomas Mechtersheimer, Founder and CEO of neurocare group, added: “We are very pleased to announce the cooperation with TVM Capital Healthcare, a strong partner with deep industry experience. This partnership allows us to accelerate neurocare’s growth in our key markets in the US, Europe and Australia and expand our geographic footprint into new regions. The implementation of our Digital Therapy Platform into clinics in the MENA region represents a new milestone in our company's growth. I want to thank all involved parties, especially bm-t Thüringen, Aescuvest and Goerg Lawyers, for their advice and support in closing this financing."

-------------------------------------------------

About TVM Capital Healthcare: TVM Capital Healthcare is an emerging markets-focused healthcare private equity firm headquartered in Dubai and Singapore, with offices in Riyadh, and Ho Chi Minh City. The Firm invests expansion and growth capital in healthcare companies to improve local access to quality care. Investment and operating partners as well as a strong group of senior advisors have long-standing international track records in healthcare investing, active board work, contributions to strategy development and implementation, and deep healthcare operations experience. The Firm partners with local Middle Eastern and Southeast Asian management teams to build domestic or regional sector champions and selectively back companies from Europe or North America for expansion into the Firm’s two key target geographies.  TVM Capital Healthcare’s investment and operating approach combines strong commercial value creation and returns with impact and responsible (ESG) investing. www.tvmcapitalhealthcare.com.

About neurocare group AG: neurocare is transforming mental health care by bringing a much-needed approach to the field: an integrated, personalized treatment based on strong clinical evidence. neurocare’s digital therapy platform (DTP) is the first of its kind in the area of mental health and is empowering doctors to offer their patients the best care for a variety of psychological or neurological conditions. Following a detailed assessment of the patient's condition, neurocare supports clinicians in developing individualized therapy plans that are designed to lead to strong, sustainable outcomes for patients, improving their self-regulation, resilience and social skills, while being cost effective for the healthcare system. These therapy plans integrate innovative methods and tools, such as psychotherapy, neuromodulation and sleep hygiene, as well as medication, to best help each individual patient. This inclusive approach utilizing the DTP is strongly supported by data published in leading scientific journals which showed response rates of ~65% and >55% remission, with very few side effects. neurocare’s DTP is currently used in the company’s clinics across the US, the Netherlands and Australia, as well as in a growing number of third-party clinics.

www.neurocaregroup.com
 

For media inquiries, please contact:

TVM Capital Healthcare:  Samantha Armstrong, the pr company, Email: samantha@the-prcompany.com

neurocare group: Sally Remington, Global Marketing Manager, neurocare group AG Email: media@neurocaregroup.com